| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 340.28% | £308,193.63 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 254.82% | £248,374.64 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 172.49% | £190,744.67 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 46.18% | £102,328.88 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 35.68% | £94,974.39 |
| Lord Mance |
|
Stryker / NYQ:SYK | 11.14% | £77,799.28 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 1.96% | £71,370.88 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -17.62% | £57,668.63 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -20.28% | £55,801.33 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -35.52% | £45,134.98 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -78.52% | £15,036.25 |